Literature DB >> 347942

Damage to hyphal forms of fungi by human leukocytes in vitro. A possible host defense mechanism in aspergillosis and mucormycosis.

R D Diamond, R Krzesicki, B Epstein, W Jao.   

Abstract

Evidence suggests that neutrophils are important in host defenses against invasive aspergillosis and mucormycosis, although hyphae in these lesions are too large to be phagocytized. Interactions of neutrophils with hyphae of Aspergillus fumigatus and Rhizopus oryzae were studed in vitro. Light and electron microscopic observations indicated that neutrophils attached to and spread over the surfaces of hyphae, even in the absence of serum. This was followed by dramatic morphologic changes which suggested severe damage and probably death of hyphae. An assay of neutrophil-induced reduction of uptake of radioisotopes was used to quantitate damage to the fungi by neutrophils from normal subjects. Damage to hyphae was inhibited by a variety of compounds which are known to affect neutrophil surface functions, motility, and metabolism. Use of inhibitors of oxidative microbicidal mechanisms of neutrophils indicated the central importance of these mechanisms in damage to hyphae. Inhibitors of neutrophil cationic proteins altered damage only to Rhizopus. Damage to hyphae by lysozyme suggested that it may play a secondary role in the neutrophil, primarily against Aspergillus. This new nonphagocytic mechanism may play an important role in host defenses against these and other hyphal forms of fungi.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 347942      PMCID: PMC2018207     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  35 in total

1.  Evidence for hydroxyl radical production by human neutrophils.

Authors:  A I Tauber; B M Babior
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

2.  Bacteremia and fungemia complicating neoplastic disease. A study of 364 cases.

Authors:  C Singer; M H Kaplan; D Armstrong
Journal:  Am J Med       Date:  1977-05       Impact factor: 4.965

3.  Experimental aspergillosis in rats infected via intraperitoneal and subcutaneous routes.

Authors:  K J Turner; R Hackshaw; J Papadimitriou; J D Wetherall; J Perrott
Journal:  Immunology       Date:  1975-07       Impact factor: 7.397

4.  Interference with normal phagosome-lysosome fusion in macrophages, using ingested yeast cells and suramin.

Authors:  P D Hart; M R Young
Journal:  Nature       Date:  1975-07-03       Impact factor: 49.962

5.  Aspergillus pneumonia in hematologic malignancy. Improvements in diagnosis and therapy.

Authors:  J E Pennington
Journal:  Arch Intern Med       Date:  1977-06

6.  Iodination by human polymorphonuclear leukocytes: a re-evaluation.

Authors:  S J Klebanoff; R A Clark
Journal:  J Lab Clin Med       Date:  1977-03

7.  Fungal infections after renal transplantation.

Authors:  Z F Braf; G Altmann; E Ostfeld
Journal:  Isr J Med Sci       Date:  1976-07

8.  Causes of death in adults with acute leukemia.

Authors:  H Y Chang; V Rodriguez; G Narboni; G P Bodey; M A Luna; E J Freireich
Journal:  Medicine (Baltimore)       Date:  1976-05       Impact factor: 1.889

9.  Treatment of invasive aspergillosis: relation of early diagnosis and treatment to response.

Authors:  J Aisner; P H Wiernik; S C Schimpff
Journal:  Ann Intern Med       Date:  1977-05       Impact factor: 25.391

10.  2-Deoxyglucose selectively inhibits Fc and complement receptor-mediated phagocytosis in mouse peritoneal macrophages II. Dissociation of the inhibitory effects of 2-deoxyglucose on phagocytosis and ATP generation.

Authors:  J Michl; D J Ohlbaum; S C Silverstein
Journal:  J Exp Med       Date:  1976-12-01       Impact factor: 14.307

View more
  63 in total

1.  Involvement of CD14 and toll-like receptors in activation of human monocytes by Aspergillus fumigatus hyphae.

Authors:  J E Wang; A Warris; E A Ellingsen; P F Jørgensen; T H Flo; T Espevik; R Solberg; P E Verweij; A O Aasen
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

2.  Intubation practice on cadavers should stop.

Authors:  Alison Tonks
Journal:  BMJ       Date:  1992-08-08

3.  Role of neutrophils in invasive aspergillosis.

Authors:  Marta Feldmesser
Journal:  Infect Immun       Date:  2006-10-09       Impact factor: 3.441

Review 4.  Pulmonary Aspergillus intracavitary colonization (PAIC).

Authors:  L C Severo; G R Geyer; N S Porto
Journal:  Mycopathologia       Date:  1990-11       Impact factor: 2.574

5.  Fatal fungal peritonitis in an adolescent on continuous ambulatory peritoneal dialysis: association with deferoxamine.

Authors:  M Nakamura; W B Weil; D B Kaufman
Journal:  Pediatr Nephrol       Date:  1989-01       Impact factor: 3.714

6.  Virulence of Aspergillus fumigatus double mutants lacking restriction and an alkaline protease in a low-dose model of invasive pulmonary aspergillosis.

Authors:  J M Smith; C M Tang; S Van Noorden; D W Holden
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

7.  Purification and characterization of factors produced by Aspergillus fumigatus which affect human ciliated respiratory epithelium.

Authors:  R Amitani; G Taylor; E N Elezis; C Llewellyn-Jones; J Mitchell; F Kuze; P J Cole; R Wilson
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Tumor necrosis factor alpha enhances antifungal activities of polymorphonuclear and mononuclear phagocytes against Aspergillus fumigatus.

Authors:  E Roilides; A Dimitriadou-Georgiadou; T Sein; I Kadiltsoglou; T J Walsh
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

9.  Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies.

Authors:  J R Boelaert; M de Locht; J Van Cutsem; V Kerrels; B Cantinieaux; A Verdonck; H W Van Landuyt; Y J Schneider
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

10.  Cerebral mucormycosis in diabetic mice after intrasinus challenge.

Authors:  A R Waldorf; R D Diamond
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.